(EN) Elranatamab post trial access: an open-label, single-arm study for participants with multiple myeloma continuing from Pfizer-sponsored Elranatamab clinical studies
MagnetisMM15
NCT06057402
 Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
|
Nancy Renouf
514-934-1934 poste 35718
|
Étude comparant le médicament à l’étude, appelé elranatamab, et l’elotuzumab, la pomalidomide et la dexaméthasone (EPd), la pomalidomide, le bortézomib et la dexaméthasone (PVd) ou le carfilzomib et la dexaméthasone (Kd) chez des personnes vivant avec un myélome multiple qui est revenu après un ou plusieurs traitements antérieurs
MagnetisMM-32 (C1071032)
NCT06152575
Actif en recrutement
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
|
Maia Labelle
514-338-2222 poste 2818
|
(EN) A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
MonumenTAL-6
NCT06208150
Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
|
Marie-Pier Lecours-Cyr
514-252-3400 poste 5037
|
(EN) A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
MajesTEC-9
NCT05572515
Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
|
Marie-Pier Lecours-Cyr
514-252-3400 poste 5037
|
(EN) A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
CARTITUDE-5
NCT04923893
Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
|
Nathalie Lachapelle
514-252-3400 poste 4471
|
Groupe d'étude en oncologie du Québec